WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Hematogenix
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Cell and Gene Therapy
BioMarin Pharmaceutical Inc. | December 17, 2021
BioMarin Pharmaceutical Inc. and Skyline Therapeutics a gene and cell therapy company focused on developing novel treatments for unmet medical needs, announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus gene therapies to treat genetic cardiovascular diseases. The partnership will leverage Skyline Therapeutics' integrated AAV gene therapy platform based on its proprietary vector engineer...
Medical
Aruna Bio | June 01, 2022
Aruna Bio, Inc., a leader in the development of neural exosome based therapeutics for the treatment of neurodegenerative diseases, today announced that it has received funding from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health of Health to advance AB126™, a multimodal neuroprotective and regenerative neural stem cell extracellular vesicle (NSC EV) product, to treat Traumatic Brain Injury (TBI). The succ...
EXUMA Biotech Corp. | December 22, 2021
EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...
Industrial Impact
Sartorius Stedim Biotech S.A. | February 08, 2022
Sartorius Stedim Biotech, a leading partner of the biopharma industry, announced today that it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission. The transaction had already been agreed upon at the beginning of 2021. The business acquired generated sales of around 40 million euros in 2020 at a double-digit profit margin; final figures for 2021 are not yet available. The majority of the approximately 100 e...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE